-11.2%
CRM vs MRNA
+909.7%
-920.9%
-43.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.1% | -6.5% | +4.5% | -1.9% |
| 7D | -3.7% | +8.4% | -12.1% | -3.8% |
| 30D | -1.1% | +28.8% | -30.0% | -1.7% |
| 3M | +15.5% | +329.2% | -313.8% | +10.0% |
| 6M | +19.5% | +416.9% | -397.5% | +14.8% |
| YTD | -15.5% | +718.8% | -734.3% | -21.5% |
| 1Y | -11.2% | +924.9% | -936.1% | -21.7% |
| All | -11.2% | +909.7% | -920.9% | -21.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling